Grape King Bio Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	10yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Feb 27

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Nov 20

CEO

Grape King Bio heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sheng-Lin Tseng	Chairman & GM	15.4yrs	geen gegevens	0.73% NT$ 168.5m
Nick Hung	Accounting Supervisor	10.8yrs	geen gegevens	geen gegevens
Bing-Jyun Cuei	Chief Legal Officer	3.3yrs	geen gegevens	geen gegevens

10.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van 1707 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sheng-Lin Tseng	Chairman & GM	15.4yrs	geen gegevens	0.73% NT$ 168.5m
Mei-Ching Tseng	Director	9.4yrs	geen gegevens	1.99% NT$ 457.9m
Jue-Jia Chang	Director	15.4yrs	geen gegevens	geen gegevens
Chih-Wei Lai	Director	6.5yrs	geen gegevens	0.44% NT$ 101.2m
Yen-Shiang Huang	Director	6.5yrs	geen gegevens	0.14% NT$ 31.5m
Hsing-Chun Chen	Director	3.3yrs	geen gegevens	1.08% NT$ 247.3m
Jing-Ning Chen	Independent Director	3.3yrs	geen gegevens	geen gegevens
Chi J. Yu	Independent Director	less than a year	geen gegevens	geen gegevens
Pang-Chung Chin	Independent Director	less than a year	geen gegevens	geen gegevens
Ting-Ju Chen	Independent Director	less than a year	geen gegevens	geen gegevens
Jia-Fong Chai	Representative Director	less than a year	geen gegevens	geen gegevens
Bang Jin	Independent Director	less than a year	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 1707 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Grape King Bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Grape King Bio Ltd Announces Changes to Remuneration Committee

Grape King Bio Ltd Approves Changes to the Board

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Less than half of directors are independent

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.81 (vs NT$2.48 in 3Q 2023)

Grape King Bio Ltd to Report Q3, 2024 Results on Nov 11, 2024

Now 21% overvalued

Second quarter 2024 earnings: EPS misses analyst expectations

Grape King Bio Ltd Announces Changes to Remuneration Committee

Grape King Bio Ltd to Report Q2, 2024 Results on Aug 12, 2024

Grape King Bio's (TWSE:1707) Dividend Will Be NT$6.90

Upcoming dividend of NT$6.90 per share

Grape King Bio (TWSE:1707) Will Pay A Dividend Of NT$6.90

Dividend of NT$6.90 announced

Grape King Bio Ltd Approves Changes to the Board

Grape King Bio Ltd Announces Dividend, Payable on July 18, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Grape King Bio Ltd to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Price target decreased by 12% to NT$170

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Upcoming dividend of NT$6.90 per share at 3.9% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% undervalued after recent price drop

Now 21% undervalued

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of NT$6.10 per share

Grape King Bio Ltd Announces Cash Dividend

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Grape King Bio Ltd Applies to FDA for A Phase II Clinical Trial Review in Humans for GKAC

Third quarter 2021 earnings released: EPS NT$2.04 (vs NT$2.23 in 3Q 2020)

Price target decreased to NT$195

Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$2.09 in 2Q 2020)

Upcoming dividend of NT$6.40 per share

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

Grape King Bio (TPE:1707) Knows How To Allocate Capital

Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Grape King Bio's (TPE:1707) Anemic Earnings Might Be Worse Than You Think

Revenue beats expectations

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Full year 2020 earnings released: EPS NT$9.34 (vs NT$9.63 in FY 2019)

Grape King Bio Ltd, Annual General Meeting, May 28, 2021

New 90-day high: NT$181

Grape King Bio Ltd announced that it expects to receive TWD 2.01467 billion in funding from Uni-President Enterprises Corp.

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Price target lowered to NT$206

Third quarter 2020 earnings released: EPS NT$2.23

Earnings beat expectations, revenue disappoints

New 90-day low: NT$167

New 90-day low: NT$176

New 90-day low - NT$178

New 90-day low - NT$184

First half earnings released

CEO

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur